Rewriting the RNA code: an m6a-centric framework to classify tumors and guide combination therapies

Key Points

• The framework offers a novel approach to tumor classification and vulnerability prediction for therapies.
• It emphasizes the importance of targeting the m6A epitranscriptome in oncology for better outcomes.
• By translating epitranscriptomic insights, personalized and biomarker-guided therapies can be developed for patients.
• This strategy may significantly enhance treatment efficacy by overcoming the challenges of context-dependency.

Abstract